Ibex Investors LLC lessened its position in Theravance Biopharma Inc (NASDAQ:TBPH) by 10.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,123 shares of the biopharmaceutical company’s stock after selling 3,681 shares during the period. Ibex Investors LLC’s holdings in Theravance Biopharma were worth $728,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of TBPH. FNY Investment Advisers LLC acquired a new position in shares of Theravance Biopharma in the fourth quarter valued at approximately $42,000. Quantamental Technologies LLC purchased a new stake in Theravance Biopharma in the fourth quarter valued at approximately $102,000. Amundi Pioneer Asset Management Inc. grew its holdings in Theravance Biopharma by 34.1% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 5,500 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,400 shares during the period. SG Americas Securities LLC purchased a new stake in Theravance Biopharma in the first quarter valued at approximately $156,000. Finally, Citigroup Inc. grew its holdings in Theravance Biopharma by 258.5% in the fourth quarter. Citigroup Inc. now owns 6,481 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 4,673 shares during the period. 85.14% of the stock is owned by institutional investors and hedge funds.
TBPH traded down $0.12 during trading on Wednesday, hitting $21.25. 701 shares of the company’s stock were exchanged, compared to its average volume of 251,846. Theravance Biopharma Inc has a 1 year low of $20.55 and a 1 year high of $35.48. The company has a market cap of $1.20 billion, a P/E ratio of -5.24 and a beta of 1.68.
Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.14). Theravance Biopharma had a negative return on equity of 2,632.27% and a negative net margin of 388.61%. The business had revenue of $5.34 million for the quarter, compared to analysts’ expectations of $16.45 million. As a group, equities research analysts anticipate that Theravance Biopharma Inc will post -4.75 EPS for the current year.
In other Theravance Biopharma news, SVP Sharathchandra S. Hegde sold 9,033 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $24.71, for a total transaction of $223,205.43. Following the completion of the sale, the senior vice president now directly owns 270,134 shares in the company, valued at $6,675,011.14. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 6.60% of the stock is owned by insiders.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating and set a $29.00 target price for the company in a report on Monday, February 11th. BidaskClub downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, January 31st. Cantor Fitzgerald assumed coverage on shares of Theravance Biopharma in a report on Monday, January 28th. They issued a “buy” rating and a $55.00 target price for the company. Finally, ValuEngine downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, January 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $43.40.
TRADEMARK VIOLATION NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2019/05/15/ibex-investors-llc-has-728000-stake-in-theravance-biopharma-inc-tbph.html.
Theravance Biopharma Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Read More: What is a resistance level?
Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma Inc (NASDAQ:TBPH).
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.